Immunovant Inc., formerly called Health Sciences Acquisitions Corp., has closed its acquisition of Immunovant Sciences in a deal valued at about $395 million.

The merger, announced in October, makes the original Immunovant Sciences a wholly owned subsidiary of the former Health Sciences, the combined company adopting the name Immunovant.

Shareholders of Health Sciences approved the deal at a Dec. 16 meeting, and the new company will trade under the symbol IMVT on Nasdaq.

Immunovant specializes in autoimmune diseases and is developing the drug IMVT-1401 with its partner, HanAll Biopharma.